Skip to search formSkip to main contentSkip to account menu

Iodine I 123 Anti-CEA Recombinant Diabody T84.66

A radioimmunoconjugate comprised of a recombinant scFv dimer diabody of a monoclonal antibody against human carcinoembryonic antigen (CEA) labeled… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Radioimmunotherapy and nuclear imaging (immuno-PET/SPECT) of cancer with radiometal-labeled antibody fragments or peptides is… 
2010
2010
Purpose: The rapid tumor targeting and pharmacokinetic properties of engineered antibodies make them potentially suitable for use… 
Highly Cited
2009
Highly Cited
2009
Mesenchymal stem cells (MSCs) are appealing as gene therapy cell vehicles given their ease of expansion and transduction. However… 
Highly Cited
2008
Highly Cited
2008
Anti-CD30 diabodies were engineered with two cysteine mutations for site-specific drug conjugation in each chain of these… 
Highly Cited
2007
Highly Cited
2007
The bioluminescent protein Gaussia luciferase (GLuc) was fused to an anti-carcinoembryonic antigen (CEA) antibody fragment, the… 
Highly Cited
2006
Highly Cited
2006
Purpose: Bispecific antibodies (BsAb) have been exploited as both cancer immunodiagnostics and cancer therapeutics and show… 
Highly Cited
2006
Highly Cited
2006
An anti-carcinoembryonic antigen (CEA) antibody fragment, the anti-CEA diabody, was fused to the bioluminescence enzyme Renilla… 
2002
2002
Abstract. In cancer immunotherapy research, many bispecific antibodies (BsAbs) have been developed for directing T cells toward… 
Highly Cited
1999
Highly Cited
1999
CD16/CD30 bispecific monoclonal antibodies can induce remissions of Hodgkin's disease refractory to chemo- and radiotherapy…